Perrigo Company plc Payments of Debt Restructuring Costs
Perrigo Company plc (PRGO) reported Payments of Debt Restructuring Costs of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtRestructuringCosts · last filed 2025-02-28
- Perrigo Company plc payments of debt restructuring costs for the quarter ending 2018-12-31 was $0.00.
- Perrigo Company plc payments of debt restructuring costs for the quarter ending 2018-09-29 was $0.00.
- Perrigo Company plc payments of debt restructuring costs for the quarter ending 2017-12-31 was $0.00.
- Perrigo Company plc payments of debt restructuring costs for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- Perrigo Company plc payments of debt restructuring costs for fiscal 2024 was $0.00.
- Perrigo Company plc payments of debt restructuring costs for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Perrigo Company plc payments of debt restructuring costs for fiscal 2022 was $12.20M.
- Perrigo Company plc payments of debt restructuring costs for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Payments of Debt Restructuring Costs 3 month | Payments of Debt Restructuring Costs 6 month | Payments of Debt Restructuring Costs 9 month | Payments of Debt Restructuring Costs 12 month | Payments of Debt Restructuring Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-28 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-02-28 | ||||
| 2022-12-31 | $12.20M 10-K · filed 2025-02-28 | $0.00 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 | ||||
| 2020-12-31 | $19.00M 10-K · filed 2023-02-28 | ||||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 | ||
| 2018-09-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-09 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $116.10M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $116.10M 10-Q · filed 2018-11-08 | |||
| 2017-07-01 | $116.10M 10-Q · filed 2018-08-09 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $600.00K derived: sum of 2 quarters · filed 2019-02-27 | $600.00K 10-K · filed 2019-02-27 | ||
| 2016-10-01 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $600.00K 10-Q · filed 2017-11-09 | |||
| 2016-07-02 | $0.00 10-Q · filed 2017-08-10 | ||||
| 2015-12-31 | $0.00 10-K · filed 2018-03-01 | ||||
| 2015-09-26 | $0.00 10-Q/A · filed 2017-05-23 | ||||
| 2015-06-27 | $0.00 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |